- Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, recently received conditional marketing authorisation in Europe from the European Commission
- Exclusive licensing and supply agreements have been granted to Medexus for the Canadian commercialization rights for Zemcelpro® (if approved by Health Canada)
MONTREAL, June 10, 2026 /PRNewswire/ -- ExCellThera Inc. ("ExCellThera"), a global leader in blood stem cell expansion and metabolic fitness technologies, together with its wholly owned subsidiary Cordex Biologics ("Cordex"), today announced exclusive licensing and supply agreements granting Medexus the Canadian commercialization rights for Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy.
Zemcelpro® is a novel personalized cryopreserved hematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. The product is used to treat hematological malignancies (blood cancers), such as leukemias and myelodysplasias. Given the product's current stage of development in Canada, Medexus does not expect to begin commercializing the product before calendar year 2028 (depending on available regulatory pathways). As part of the regulatory process, Medexus intends to seek Health Canada approval of the brand name Zemcelpro®.
